HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (42) Citing Articles via Google Scholar Google Scholar Articles by Aranda, J. M. Articles by Hill, J. Search for Related Content PubMed PubMed Citation Articles by Aranda, J. M., Jr. Articles by Hill, J.

Cardiac Transplant Vasculopathy^*

^* From the Heart Transplant Program, University of Florida at Shands, Gainesville, FL.

Correspondence to: Juan M. Aranda, Jr., MD, University of Florida Health Science Center, PO Box 100277, Gainesville, FL 32610-0277; e-mail: arandjm{at}medicine.ufl.edu

Study objective: Coronary allograft vasculopathy (CAV) remains the major factor limiting long-term survival after heart transplantation. The purpose of this article is to review for the nontransplant physician the concept of CAV as a disease entity after heart transplantation.

Design: A MEDLINE search from 1985 to 1999 was performed. Data on cardiac transplant vasculopathy were divided into pathology, pathophysiology, presentation, diagnosis, and treatment.

Results: CAV manifests as a unique and unusually aggressive form of coronary artery disease that differs from traditional atherosclerosis. It is believed to be caused by immunologic mechanisms that combine with nonimmunologic factors to cause endothelial injury, resulting in smooth muscle proliferation and intimal thickening. This intimal hyperplasia leads to coronary obstruction, which ultimately results in allograft failure. Diagnosis of CAV can be difficult because transplant recipients have denervated hearts and rarely present with chest pain. Various noninvasive screening methods have not proved reliable. Therefore, most transplant centers perform periodic coronary angiography for routine CAV surveillance. Treatment of CAV involves modification of risk factors and the use of pharmacologic agents that alter vascular physiology. Revascularization procedures continue to play a role as palliative therapy, but are limited in their effectiveness by the diffuse nature of this disease.

Conclusion: Cardiac transplant vasculopathy continues to play a major dilemma regarding posttransplant care. Further research is needed to develop successful preventive and therapeutic strategies that may alter the course of this disease.

Key Words: coronary artery disease • heart transplant • vasculopathy

This article has been cited by other articles:

				A. J. Bergman, J. Burke, P. Larson, A. O. Johnson-Levonas, L. Reyderman, P. Statkevich, T. Kosoglou, H. E. Greenberg, W. K. Kraft, G. Frick, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J. Clin. Pharmacol., March 1, 2006; 46(3): 321 - 327. [Abstract] [Full Text] [PDF]

				S. de Denus, A. Al-Jazairi, E. Loh, M. Jessup, E. J Stanek, and S. A Spinler Dyslipidemias and HMG-CoA Reductase Inhibitor Prescription in Heart Transplant Recipients Ann. Pharmacother., July 1, 2004; 38(7): 1136 - 1141. [Abstract] [Full Text] [PDF]

				T. Hattori, H. Shimokawa, M. Higashi, J. Hiroki, Y. Mukai, K. Kaibuchi, and A. Takeshita Long-Term Treatment With a Specific Rho-Kinase Inhibitor Suppresses Cardiac Allograft Vasculopathy in Mice Circ. Res., January 9, 2004; 94(1): 46 - 52. [Abstract] [Full Text] [PDF]

				J. Myers, O. Geiran, S. Simonsen, A. Ghuyoumi, and L. Gullestad Clinical and Exercise Test Determinants of Survival After Cardiac Transplantation Chest, November 1, 2003; 124(5): 2000 - 2005. [Abstract] [Full Text] [PDF]